Jules Lin, MD

Jules Lin, M.D. is a faculty member in the Section of Thoracic Surgery at the University of Michigan and is the surgical director of the Lung Transplant Program. He is the inaugural Mark B. Orringer Professor. He is currently serving on the Robotic Surgery Steering Committee. He is also involved in establishing national guidelines as a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer Panel and the American College of Surgeons Surgical Standards Manual, Lung Group.

Dr. Lin was a Phi Beta Kappa graduate of Indiana University and received his undergraduate degree with highest distinction in 1995. He received his medical degree from Harvard Medical School in 1999 and completed his General Surgical Residency in 2006 at the University of Michigan. During this time, he also completed a Surgical Critical Care Fellowship in 2003 and a research fellowship in the Thoracic Surgery Tumor Biology Laboratory in 2004 for which he received the Moses Gunn Young Investigator and James Crudup Awards. He completed his Cardiothoracic Surgery Residency at the University of Washington.

His research interests include investigating the molecular biology of esophageal and lung carcinoma and translating these findings into new techniques for screening, staging, and tailoring therapies for individual patients.

Clinical Specialization:

Dr. Lin specializes in general thoracic surgery and is interested in the treatment of lung and esophageal cancer, minimally-invasive approaches, tracheobronchial resection and reconstruction, sympathectomy for hyperhidrosis, and lung transplantation.

General thoracic surgery, robotic surgery, lung and esophageal cancer, minimally-invasive surgery, tracheobronchial resection and reconstruction, sympathectomy for hyperhidrosis, and lung transplantation.

University of Michigan Health participates with most health insurance plans.

Dr. Lin is working in collaboration with David Beer, PhD in investigating the molecular changes involved in the pathogenesis of thoracic malignancies. He has a particular interest in the changes involved in the progression from Barrett's metaplasia to esophageal adenocarcinoma. As a member of the Thoracic Tumor Biology Laboratory, he hopes to translate these results into tailored therapies for patients with tumors expressing specific molecular targets and to discover novel diagnostic, staging and treatment modalities. Through his research, Dr. Lin has identified several novel molecular changes involved in the pathogenesis of esophageal adenocarcinoma including the overexpression of melanoma associated antigens (MAGE), the L-type amino acid transporter-1 (LAT-1), and the ubiquitin-conjugating enzyme E2C (UBE2C) as well as investigating specific inhibitors and potential therapeutic agents.

He is currently investigating potential targets in the treatment and prevention of metastatic disease as well as the modulation of chemoresistance. He hopes to identify molecular changes associated with chemoresistance in patients both as predictors of response identifying patients who should undergo preoperative chemoradiation as well as potential targets to modulate and increase tumor chemosensitivity.